Delivery Order HHSN261201200034I-HHSN26100012
Award Date 9/1/17
Potential Completion Date 4/30/22
Potential Value $658K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,686,205.95 delivery order contract awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a randomized pre-surgical clinical trial evaluating alternative dosing regimens of the cancer drug exemestane in postmenopausal women with early-stage estrogen receptor-positive breast cancer. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early phase clinical research on new...
- The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer...
- This is a contract awarded by the National Cancer Institute (NCI), an institute within the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center. The $2,186,264.78 contract is for a randomized, double-blind, placebo-controlled study of a topical breast cancer prevention agent, 4-hydroxytamoxifen gel, in women with dense breast tissue. This contract was issued under the NCI's Cancer Prevention Agent Development Program, which supports early phase clinical...
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
- This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
- This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
- This federal contract award is for the National Cancer Institute's Cancer Prevention Agent Development Program. The prime contractor is The University of Texas M.D. Anderson Cancer Center, a comprehensive cancer research and treatment center. The contract has a ceiling value of $4,248,160.62 and does not use a set-aside designation. The contract supports early phase clinical research, with the objective of developing cancer prevention agents. It includes subcontracts with several universities...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $849,016 contract, which runs from September 17, 2018 to December 16, 2022, supports the "Rank Ligand Inhibition - A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer" project under the Preclinical...
- The National Cancer Institute awarded a Firm Fixed Price Delivery Order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, valued at $1,121,090.00. The contract is part of the PREVENT Preclinical Drug Development Program and supports preclinical efficacy and intermediate endpoint biomarker studies targeting the PARP pathway for the prevention of breast cancer. The contract has a period of performance through May 31, 2026 and is not set...
- This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...